FIELD: medicine; endocrinology.
SUBSTANCE: invention relates to medicine, specifically to endocrinology, and can be used for personalized approach to choosing method for treatment of Graves' disease. Perform single blood sampling and testing. Determine the percentage of regulatory T cells- CD3+CD4+CD127LowCD25High and activated B-lymphocytes - CD19+CD23+ by flow cytometry. Calculate the value of B-cell regulation coefficient (BCR) according to the formula: BCR = activated B-lymphocytes/regulatory T-cells. With a BCR value is equal to or lower than 0.74, radioiodine therapy is chosen. With a BCR value of 0.75 to 1.32, pharmacological therapy is chosen. With a WRC value is equal to or higher than 1.33 - surgical treatment is chosen.
EFFECT: method provides the possibility of an effective personalized approach to the choice of a method for treatment of Graves' disease by determination of regulatory T-cells and activated B-lymphocytes percentage.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING RADIOIODINE THERAPY FOR GRAVES' DISEASE | 2022 |
|
RU2791390C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF RELAPSE IN THE MEDICAL TREATMENT OF GRAVES' DISEASE | 2021 |
|
RU2778614C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF ENDOCRINE OPHTHALMOPATHY IN PATIENTS WITH GRAVES DISEASE BY DETECTING ANTI-THYROID PEROXIDASE ANTIBODIES | 2011 |
|
RU2460072C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR TYPE 1 AND 2 CORDARON-INDUCED THYROTOXICOSIS | 2011 |
|
RU2478969C1 |
| METHOD OF ESTIMATING EFFICIENCY OF DIFFUSE TOXIC GOITER THERAPY WITH RADIOACTIVE IODINE | 2008 |
|
RU2373848C1 |
| METHOD FOR PREDICTING DIFFUSE TOXIC GOITER CLINICAL COURSE | 2005 |
|
RU2291434C1 |
| METHOD OF TWO-STAGE SURGICAL TREATMENT OF DIFFUSE TOXIC GOITER | 2023 |
|
RU2812101C1 |
| METHOD FOR INDIVIDUAL DOSAGE OF RADIOIODINE-131 IN TREATING PATIENTS WITH TOXIC GOITER | 2009 |
|
RU2417736C1 |
| METHOD FOR DETERMINING INDIVIDUAL ACTIVITY OF 131-IODINE FOR RADIOIODINE THERAPY OF THYROTOXICOSIS AND PREDICTION OF TIME FOR ACHIEVING A SAFE LEVEL OF 131-IODINE ACTIVITY IN THE PATIENT'S BODY AFTER ADMINISTERING INDIVIDUAL 131-IODINE ACTIVITY | 2019 |
|
RU2722568C1 |
| METHOD FOR EARLY DIAGNOSIS OF AN ACTIVE PHASE OF ENDOCRINE OPHTHALMOPATHY | 2018 |
|
RU2687082C1 |
